Quantcast

Industry news that matters to you.  Learn more

Biodesix Blood-Based Diagnostic Testing Approach To PD-L1 Detection Shows Concordance with Immunohistochemistry

Biodesix presented preliminary data evaluating a blood-based PD-L1 assay to identify patients who may benefit from cancer immunotherapies. The data were presented last week at the AACR-NCI-EORTC conference. The study was conducted in collaboration with Dr. Michael Pritchett, from FirstHealth Moore Regional Hospital, Pinehurst Medical Clinic, and Dr. Jiaxin Niu, from Banner MD Anderson Cancer Center.

Singapore Scientists Develop New DNA Technology to Detect Breast Cancer Relapse

Researchers in Singapore, together with international collaborators from Denmark and USA, have successfully identified a unique biomarker that is strongly associated with breast cancer relapse. This finding has led to the development of a simple blood test which has numerous clinical applications, such as detecting relapse early and testing treatment efficacy. The study was recently published in scientific journal Nature Medicine in September 2017.

Two Migration Proteins Boost Predictive Value of Pancreatic Cancer Biomarker

Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early stage disease, a research team from The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

Blood-based Diagnostic Assay from Biodesix Measures Immunotherapy Biomarker PD-L1

New data from Biodesix® evaluating an assay in development demonstrated the potential to measure circulating PD-L1 through mRNA in blood through multiplexed droplet digital™ PCR (ddPCR, Bio-Rad, Inc.) detection. The assay uses proprietary RNA isolation methods consistent with Biodesix’s commercialized GeneStrat® ALK, ROS1, and RET variant tests. Existing immunohistochemistry (IHC) PD-L1 tissue tests are used to identify patients who may benefit from cancer immunotherapies. The data were presented last week at the ASCO-SITC Clinical Immuno-Oncology Program in Orlando, Florida.

Parkinsonian Disorder Differentiation Using Blood Biomarker

A blood biomarker, neurofilament light chain (NfL), may help differentiate between Parkinson’s disease (PD) and atypical parkinsonian disorders (APD), according to a study published in Neurology.